EDARBYCLOR (Azilsartan Kamedoxomil; Chlorthalidone) Patent Expiration, LOE Window & CMS Spending

EDARBYCLOR (Azilsartan Kamedoxomil; Chlorthalidone) by Azurity: FDA Orange Book core substance LOE 2030-02-04 (last listed 2031-07-01), 1 AB generics, $0 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN202331 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-02-04
Last Listed Patent or Exclusivity Date2031-07-01
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 24.3% 2-yr change)